Ben Sousa Sells 2,000 Shares of ICU Medical, Inc. (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) insider Ben Sousa sold 2,000 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $137.36, for a total transaction of $274,720.00. Following the sale, the insider now directly owns 479 shares in the company, valued at approximately $65,795.44. This represents a 80.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ICU Medical Stock Up 0.6%

Shares of NASDAQ ICUI opened at $141.38 on Friday. The firm has a market capitalization of $3.48 billion, a PE ratio of -30.94 and a beta of 0.87. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 1 year low of $100.91 and a 1 year high of $196.26. The firm’s 50-day moving average is $140.85 and its 200-day moving average is $153.95.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.49. The company had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.96 EPS. Equities analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

ICUI has been the topic of a number of research analyst reports. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. Raymond James reduced their target price on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a research note on Friday, May 9th. Finally, KeyCorp reduced their target price on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $192.67.

Institutional Trading of ICU Medical

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of ICU Medical by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock valued at $416,176,000 after acquiring an additional 17,805 shares during the period. JPMorgan Chase & Co. raised its position in shares of ICU Medical by 7.4% in the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock valued at $109,920,000 after acquiring an additional 49,108 shares during the period. Ameriprise Financial Inc. raised its position in shares of ICU Medical by 18.5% in the 1st quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier’s stock valued at $96,326,000 after acquiring an additional 108,493 shares during the period. Dimensional Fund Advisors LP raised its position in shares of ICU Medical by 18.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier’s stock valued at $83,788,000 after acquiring an additional 82,982 shares during the period. Finally, Northern Trust Corp raised its position in shares of ICU Medical by 11.1% in the 4th quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier’s stock valued at $62,431,000 after acquiring an additional 40,187 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.